RNU6-917P

Across TCGA pan-cancer cohorts, RNU6-917P RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RNU6-917P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RNU6-917P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6-917P is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

KIRC, LUAD, and LUSC are the cancer types where RNU6-917P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-917P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	IV	+0.616	<.001	12	view →
LUAD	All	III,IV	−1.465	<.001	9	view →
LUSC	Female	All	−1.871	<.001	8	view →
PAAD	Female	All	−1.230	.027	4	view →
KIRP	Female	II,III,IV	+0.320	.040	2	view →
STAD	All	II,III,IV	+0.229	.029	2	view →
LIHC	Male	All	−0.148	.010	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RNU6-917P–KIRC

Open the KIRC breakdown →